Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Sesen Bio Inc    SESN

SESEN BIO INC

(SESN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

SESEN BIO, INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/25/2019 | 04:38pm EDT
Item 5.02   Departure of Directors or Certain Officers; Election of Directors;
            Appointment of Certain Officers; Compensatory Arrangements of
            Certain Officers.

(e) Amendment of 2014 Stock Incentive Plan

At the 2019 Annual Meeting of Stockholders (the "Annual Meeting") of Sesen Bio, Inc. (the "Company") held on June 19, 2019, the Company's stockholders approved an amendment to the Company's 2014 Stock Incentive Plan (the "2014 Plan"), in order to (i) increase the number of shares reserved for issuance under the 2014 Plan by 7,908,972 shares and (ii) eliminate the "evergreen" or automatic replenishment provision of the 2014 Plan pursuant to which the number of shares authorized for issuance under the 2014 Plan is automatically increased on an annual basis (collectively, the "2014 Plan Amendment").

Summaries of the 2014 Plan and 2014 Plan Amendment are set forth in the Company's definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 30, 2019 (the "Proxy Statement"). Those summaries and the above descriptions of the 2014 Plan and 2014 Plan Amendment do not purport to be complete and are qualified in their entirety by reference to the 2014 Plan, as amended, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

Item 5.07 Submission of Matters to a Vote of Security Holders.

The following is a summary of the matters voted on at the Annual Meeting held on June 19, 2019:

a)        The stockholders of the Company elected Wendy Dixon and Jay S. Duker as
          class II directors, each for a three-year term ending at the annual
          meeting of stockholders to be held in 2022 and until their respective
          successors have been duly elected and qualified. The results of the
          stockholders' vote with respect to the election of the class II
          directors were as follows:



Name           Votes For    Votes Withheld   Broker Non-Votes

Wendy Dixon 23,747,509 2,763,161 35,384,659 Jay S. Duker 25,825,283 685,387 35,384,659



b)        The stockholders of the Company approved the 2014 Plan Amendment. The
          results of the stockholders' vote with respect to the 2014 Plan
          Amendment were as follows:



For           Against    Abstain   Broker Non-Votes
22,951,676   3,377,021   181,973      35,384,659





c)        The stockholders of the Company ratified the selection of Ernst & Young
          LLP as the Company's independent registered public accounting firm for
          the fiscal year ending December 31, 2019. The results of the
          stockholders' vote with respect to such ratification were as follows:



--------------------------------------------------------------------------------



For          Against   Abstain   Broker Non-Votes
60,792,254   491,398   611,677          0

Item 9.01 Financial Statements and Exhibits.


(d) Exhibits



(d) Exhibits.
Exhibit No. Description
10.1          2014 Stock Incentive Plan, as amended





--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SESEN BIO INC
07/18SESEN BIO, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
07/17SESEN BIO : Announces Retirement of Leslie L. Dan
BU
06/25SESEN BIO, INC. : Change in Directors or Principal Officers, Submission of Matte..
AQ
06/19SESEN BIO, INC. : Entry into a Material Definitive Agreement, Financial Statemen..
AQ
06/19SESEN BIO : XOMA Congratulates Sesen Bio on Successful Pre-BLA Meeting with FDA ..
AQ
06/19SESEN BIO : Announces Pricing of Public Offering of Common Stock and Warrants
BU
06/18SESEN BIO : Announces Proposed Public Offering of Common Stock and Warrants
BU
06/10SESEN BIO, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
06/10SESEN BIO : Announces Successful Pre-BLA Meeting with FDA for Vicinium®
BU
06/07SESEN BIO : Dr. Thomas Cannell, President and CEO of Sesen Bio, to Host Conferen..
BU
More news